Racial Disparities in GLP-1 Prescriptions for Diabetes Treatment

Why Are Minorities Less Likely to Be Prescribed GLP-1s?

Why Are Minorities Less Likely to Be Prescribed GLP-1s?
Andres Oliveira/iStock

It may seem like glucagon-like peptide-1 receptor agonists (GLP-1s) are everywhere these days. But these medications aren’t always easy to come by. And, it turns out, whether you’re prescribed one may partly depend on your racial background.

The Data Behind GLP-1 Access

GLP-1s can greatly help with regulating blood sugar and managing chronic conditions such as type 2 diabetes and obesity. But new research suggests that Black and Latino people are less likely than white people to be prescribed these potentially life-changing medications, even though there’s a higher incidence of diabetes in those populations.

Black and Latino adults are nearly twice as likely as white adults to develop type 2 diabetes.

“It’s really concerning. We see disparities in a lot of evidence-based care for a variety of reasons,” says Ajaykumar Rao, MD, an associate professor of medicine and the chief of endocrinology, diabetes, and metabolism at Lewis Katz School of Medicine at Temple University in Philadelphia. “We all need to think about what factors are playing a role in doctors not prescribing GLP-1s for people from these backgrounds.”

Why Black and Latino People Might Not Be Prescribed a GLP-1

One of the biggest barriers to equitable GLP-1 access is healthcare inequality. Minorities are more likely to be uninsured or underinsured, which can limit access to newer, expensive medications.

(That said, Black and Latino people are still less likely to be prescribed a GLP-1 across various types of insurance.)

Additionally, racial and ethnic minorities are more likely to live in areas with fewer healthcare providers or less access to cutting-edge treatments.

 This lack of availability may mean that even when a GLP-1 prescription is an option, it’s not always offered, due to logistical constraints.
Experts point to structural racism and implicit bias as contributing factors to unequal prescribing patterns. This can stem from stereotypes about patient adherence, assumptions about their preferences, or even perceptions about the person’s lifestyle choices. They also note that more research was needed to say how these factors continue to influence prescription practices.

What Makes Someone a Good Candidate for a GLP-1

Systemic inequality continues to affect treatment recommendations — even when those same medications can be just as effective for people of all races. In fact, there’s good reason to think Black and Latino people may be particularly good candidates for a GLP-1.

Black people are 30 percent more likely to have high blood pressure — a risk factor for heart disease — compared with white people, according to some statistics. Moreover, they’re also less likely to have their blood pressure under control.

“The presence of cardiovascular disease — such as a history of a heart attack, stroke, or heart failure — are aspects we think about when considering GLP-1s, because there’s proven benefits for reducing all of these events in people with diabetes,” says Dr. Rao. Because of this, he adds, it’s crucial for your physician to take a good health history and uncover any information that could be linked to these conditions.

People who have a high body mass index and a higher A1C level (a measurement of your average blood sugar levels over the past three months) also make good candidates for a GLP-1, especially because other type 2 diabetes medications aren’t always able to lower A1C levels as much as these drugs can, says Rao.

And if you have — or are at high risk of developing — chronic kidney disease (Black Americans are three times more likely than white Americans to have kidney failure; Latino Americans are 1.3 times more likely), taking a GLP-1 may also be a good option for you.

One study found that treatment with semaglutide (a type of GLP-1) reduced the risk of a major cardiovascular event by 18 percent and the risk of death from any cause by 20 percent in people with type 2 diabetes and CKD.

What to Discuss With Your Doctor

If you think you might benefit from taking a GLP-1, don’t hesitate to initiate the conversation with your doctor. And don’t feel like you need to seek out a specialist to do so. “Primary care physicians are in a great position to get people going on these medicines,” says Rao.

Before bringing questions to your doctor, Rao recommends familiarizing yourself with the American Diabetes Association’s Standards of Care, a summary of the organization’s most current recommendations, which is updated annually.

“Reading up on these can help people advocate for themselves in front of their providers,” he says. “Print those or have them on your phone and ask your doctor, ‘Are we following this?’” If the answer is no, ask why.

If your doctor determines that a GLP-1 may work for you, Rao advises asking the following questions, so you know what to expect when taking the meds:

  • What are the side effects? “It’s always important to ask this, because you don’t want to read a list of possible side effects on the box when you get home and get scared,” says Rao.
  • What might my A1C levels look like? Your provider should be able to estimate what your blood sugar levels may be after three months and after six months.
  • How do I administer it? Because many of these medications are injectables, make sure you’re comfortable with how to use them. If you’re not, ask your provider for help or for other options.

How to Make GLP-1s More Affordable

GLP-1s, while effective, are often expensive, even if insurance covers them. “Something could be covered, but then when you go to the pharmacy, you may still have an out-of-pocket cost,” says Rao.

For commercial insurance patients, there are manufacturer-supported cards or copay cards that can reduce costs, he says. If your provider’s connected with a hospital, there may also be an outpatient pharmacy offering a lower out-of-pocket cost.

Finally, Rao suggests looking into patient prescription assistance programs, but he notes that this can require a bit of work. (You or your provider may have to fill out some applications, for example.)

There’s also a generic GLP-1 called liraglutide on the market, which may be available at a lower price. While that medication could be a good fit for you, know that providers should always choose the most appropriate treatment for you and your health, Rao says.

The Takeaway

  • GLP-1 medications can significantly improve health outcomes for people with type 2 diabetes and obesity, but research suggests that many minorities are missing out.
  • Black and Latino people in particular may benefit from taking a GLP-1: Black and Latino adults are more likely to be diagnosed with diabetes and to have high blood pressure — a risk factor for heart disease — than white people.
  • Learning more about these medications, talking with your doctor, and finding ways to make them more affordable can help reduce the racial gap in GLP-1 prescriptions.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Rodriguez LA et al. Race and Ethnicity and Pharmacy Dispensing of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes. The Lancet Regional Health – Americas. June 2024.
  2. Statistics About Diabetes. American Diabetes Association.
  3. Tolbert J et al. Key Facts About the Uninsured Population. KFF. December 18, 2024.
  4. Funk C. Black Americans’ Views About Health Disparities, Experiences With Health Care. Pew Research Center. April 7, 2022.
  5. Heart Disease and Black/African Americans. U.S. Department of Health and Human Services Office of Minority Health. September 22, 2023.
  6. Social Determinants of Health and Chronic Kidney Disease. National Kidney Foundation. January 2, 2023.
  7. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes. The New England Journal of Medicine. July 11, 2024.
Additional Sources
Elise-M-Brett-bio

Elise M. Brett, MD

Medical Reviewer
Elise M Brett, MD, is a board-certified adult endocrinologist. She received a bachelor's degree from the University of Michigan and her MD degree from the Icahn School of Medicine at Mount Sinai. She completed her residency training in internal medicine and fellowship in endocrinology and metabolism at The Mount Sinai Hospital. She has been in private practice in Manhattan since 1999.

Dr. Brett practices general endocrinology and diabetes and has additional certification in neck ultrasound and fine-needle aspiration biopsy, which she performs regularly in the office. She is voluntary faculty and associate clinical professor at the Icahn School of Medicine at Mount Sinai. She is a former member of the board of directors of the American Association of Clinical Endocrinology. She has lectured nationally and published book chapters and peer reviewed articles on various topics, including thyroid cancer, neck ultrasound, parathyroid disease, obesity, diabetes, and nutrition support.
Laurel Leicht

Laurel Leicht

Author

Laurel Leicht has been a writer and editor for nearly two decades. A graduate of the College of William and Mary and the master's program at the Missouri School of Journalism, she covers a wide range of health and fitness topics, including breast cancer, various chronic conditions, mental health, and cardiovascular health.